• About
    • About Biorasi
      • Meet Biorasi

        Biorasi, founded in 2002, has partnered with global
        sponsors to enable FDA, EMA, and multi-venue
        approvals for numerous small molecules and
        biologics. Headquartered in Miami, Florida,
        Biorasi maintains office-based teams
        around the globe.

    • Our People
      • Cultivating The Future

        Biorasi hires the best – from industry and regulatory agency veterans to promising young talent on the rise. Biorasi’s leadership is made up of forward-looking visionaries with an unparalleled commitment to excellence in the services we provide to our sponsors and partners.
    • Our Board
      • Leading the Industry

        Our board is comprised of some of the most brilliant minds working in biopharma. Our directors and advisers help guide the company and act as a vital strategic asset both for Biorasi and our sponsors.
    • Careers
      • Careers

        We are looking to hire the best from inside and outside the industry. If you have an unparalleled commitment to excellence, a passion for making life better, and a drive for success, we’d like to talk to you.
  • Services
    • Study Rescue
      • Study Rescue


        Biorasi has a long track record of being able to
        right faltering programs. We have worked both
        as an integrated CRO, adding our strengths
        to a trial’s incumbent CRO, as well as a
        transition CRO, by assuming primary
        study management responsibility
        from the incumbent organization.

        Read how Biorasi can
        help rescue your trial

    • Project Management
      • Project Management

        We believe that only fundamentally sound project management can ensure trial success, and that only properly trained project managers, backed up by industry-leading processes, and innovative tools, can ensure sound project management.

    • Regulatory Services
      • Regulatory Services

        Regulatory affairs strategy is one of the biggest hurdles in running clinical trials. Increased trial complexity, regulation, and the need for multi-venue approval are driving this trend. Biorasi’s regulatory team has worked with regulatory agencies around the globe, including the most difficult venues.

    • Safety
      • Safety and Pharmacovigilance

        Biorasi’s best-in-class processes and technologies help our team identify safety trends and risks in sponsor studies quickly, and give us insight on how to resolve them without risking the trial. Fast detection, fast response, and fast resolution ensure our trials always stay on time.

    • Data Science/Biometrics
      • Data Science & Biometrics

        We make trial data an integral part of guiding trial success. Biorasi builds out standard data structures from the beginning and uses big data-style analytics to make your data immediately useful. This front-loaded approach saves sponsors time and money and minimizes risks.

    • Quality Assurance
      • Quality Assurance

        Biorasi is constantly evolving and improving, always under the guidance of quality first. Our quality team audits our internal functions as well as our sponsor studies to make sure that plans and SOPs are adhered too.

    • Program Development
      • Program Development

        We look at your projects in a global context. Biorasi’s consulting services are built around the idea that trials only realize their maximum value when they part of an optimized and effective holistic drug development program.

  • Therapeutic Areas
    • Autoimmune
      • Autoimmune

        Autoimmune is one of the fastest-growing areas of clinical research, due to increased recognition and incidence of autoimmune diseases i. Biorasi can help with all aspects of managing your next autoimmune trial.

    • Dermatology
      • Dermotology

        Dermatology trials have some very unique challenges. From difficulty in enrolling to compliance in a patient population that is typically much younger than other trials, Biorasi knows how to make your dermatology trial a success.

    • Nephrology
      • Nephrology & Pain

        Biorasi is a leading CRO in nephrology and dialysis-dependent CKD populations. No one understands the nuances of research in the dialysis population better than we do, and no one conducts these studies with our level of professionalism, and attention to the special needs of these patients.

    • Neurology
      • Neurology Trials

        Biorasi’s project managers and clinicians understand the complexities of neurodegenerative, pain, and psychiatric disorders. Our unique positioning and experience, coupled with our strong network and relationships with specialized sites give us an unparalleled advantage in neurology trials.

    • Oncology
      • Oncology Trials

        Many CROs specialize in oncology, however few have the versatility to offer full-service trial management like Biorasi. Find out how our integrative approach to oncology makes a real difference in the success of your next oncology trial.

    • Women's Health
      • Women’s Health Trials

        Trusting your women’s health trials to an expert like Biorasi guarantees every trial you run will be optimized. With years of experience and a broad portfolio of past studies, Biorasi is your best partner in women’s health clinical research.

    • Medical Devices
      • Medical Device Trials

        Medical devices are a unique field with a unique approach to regulatory approvals and clinical trials. Biorasi combines deep expertise in the specialized area of medical devices, and combines it with decades of therapeutic area excellence with our industry leading methodology.

  • Technology
    • Talos Technology

      An increasingly connected world can make your clinical trials better or just more complex. Our TALOS™ Technology Platform is built to take connections and turn them into insights, increase efficiencies and help us deliver optimized solutions for every sponsor.

      Learn More

  • Resources
  • Contact

Patients with Alzheimer’s are not treated the same everywhere. On a global level, this is immediately evident between countries through differences in diagnostic criteria. Even on a more local level, racial and ethnic disparities persist. These and other factors result in different standards of care. Multinational or not, study sites in a clinical trial must be standardized to follow the same protocol. Disparities and issues with standardization make it difficult to run successful, generalizable Alzheimer’s trials.


Venue Variability

The US may be considered one of the hubs of clinical research, but only 28% of current Alzheimer’s trials registered on are based out of the US. Why is this an issue? It’s not so important which country trials are conducted in, but it is important that the study sample in a drug trial is representative of the population that the drug will be used to treat once it is approved. If a new drug will be marketed in the US but is being tested overseas, the research participants may have different genetics, lifestyles, and cultural norms from the market population. Genetics can directly affect one’s predisposition for developing a disease and how their symptoms manifest. Lifestyle habits can do the same and can also alter clinical trial procedure adherence and outcomes. Cultural norms can influence how patients are cared for, both at doctors’ offices and at home; a disease may be either vigorously screened for or instead ignored as a taboo, dramatically affecting diagnostic and treatment rates. For example, some cultures believe that dementia is a typical part of aging and needs no treatment, or in the extreme, have a stigma around dementia so strong that patients are discouraged from seeking treatment.

In addition, each country has their own set of diagnostic and treatment guidelines that physicians follow, and those can influence the standard of care provided to patients. Multinational Alzheimer’s trials may meet resistance when trying to standardize study site physicians to a treatment protocol that contradicts how they typically treat patients. If physicians are being asked to evaluate their patients using scales or tools that they are unfamiliar with, then they are by definition less trained on the tool and possibly more likely to make inaccurate evaluations. This can result in heterogeneity or variation between sites, which is something researchers painstakingly try to avoid.

A specific example of this has been cited for the ADAS-cog tool that is used to evaluate aspects of cognitive function in Alzheimer’s patients. One estimate stated that a rater must rate at least five patients using these types of scales before they can produce reliable scores, but studies have reported that up to 40% of raters in clinical trials are using the scales without this level of experience. Different estimates of disease progression result in differences in how aggressively patients are treated and thus different standards of care.

Finally, something as simple as a language can also interfere with a trial’s ability to get accurate data if an assessment tool has been translated but not validated. It is very easy to lose meaning in translation, and this can affect a patient’s ability to understand what is being asked on survey tools, which are an important part of cognitive assessment.


Diversity Disparities

We don’t have to look overseas to find disparities in Alzheimer’s patients, says Dr. Jimmy El Hokayem, our resident expert on neurological diseases. “Because the US population is so diverse, these disparities are in our backyard. Many of my colleagues in Alzheimer’s research will attest to that. And it is a problem that we have treatments being tested in a group of people that does not demographically represent those who will be treated with the drug later on.” This goes back to the same issue of being able to generalize the results of a trial to a population. The sample must represent the population to be treated.

The demographic differences he refers to are largely race and ethnicity. Within the US, African Americans and Hispanics have much higher rates of both prevalence (number of people who have a disease at a single point in time) and incidence (number of new diagnoses over a period of time) of Alzheimer’s compared to white non-Hispanics. And who is being enrolled in Alzheimer’s trials in the US? It’s not these minority groups. There could be many reasons for this, including a tendency of clinical trials to require fluency in the English language for participation or simply a lack of access to healthcare for minority groups. Apart from this being a humanitarian crisis, a drug sponsor will suffer if the drug does not work in real life like it did in the development trials. It will not get prescribed and will fall off the market.



In order to reach enrollment numbers, it is often necessary to look outside the US for sites. So what can researchers do about these issues? For global trials, they can remain aware of these disparities and be vigilant in standardizing study sites to the protocol through training, validating assessment tools in appropriate languages, and ensuring the study sample is demographically representative of the population to be treated. Bridging studies are trials that purposely seek data across ethnic groups and can be run in parallel with phase II or III studies so that results can be better generalized. These same measures can actually be taken to combat most of the issues spawned from local disparities in addition to increasing minority ethnic groups’ accessibility to clinical trials. If these things are not done, the drug developer is directly affected when the drug does not work for the people who it is being sold to, and investments can be wasted.

Download a Sample Rescue Trial Report

Please provide your email address so we can email your sample rescue trial report.